COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,864 Articles (22,568 medRxiv, 8,296 bioRxiv)

Most recent first Previous |  Page 320: Articles 3191-3200  | Next

Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Wang, P., ZHAO, X.
10.1101/2023.08.22.554373 — Posted: 2023-08-24
Gut microbiome remains stable following COVID-19 vaccination in healthy and immuno-compromised individuals
Boston, R. H., Guan, R., Baier, S., Kalmar, L., Horner, E. C., Beristain-Covarrubias, N., Yam-Puc, J. C., Gerber, P. P., Faria, L., Kuroshchenkova, A., Lindell, A. E., Blasche, S., Correa-Noguera, A., Elmer, A., Saunders, C., Bermperi, A., Jose, S., Kingston, N., COVID-19 BioResource Collaboration, , Grigoriadou, S., Staples, E., Buckland, M., Parkinson, C., Lear, S., Matheson, N. J., Benes, V., Thaventhiran, J. E., Patil, K. R.
10.1101/2023.08.23.554506 — Posted: 2023-08-24
Comparison of SARS-CoV-2 variants in primary human nasal cultures indicates Delta as most cytopathic and Omicron as fastest replicating
Tanneti, N. S., Patel, A. K., Tan, L. H., Marques, A. D., Perera, R. A., Sherrill-Mix, S., Kelly, B. J., Collman, R. G., Rodino, K., Lee, C., Bushman, F. D., Cohen, N. A., Weiss, S. R.
10.1101/2023.08.24.553565 — Posted: 2023-08-24
Deep proteome analysis of time-series human plasma samples applied to Covid-19 antibody test
Fukuda, T., Nakayama, A., Chikaoka, Y., Bando, Y., Kawamura, T.
10.1101/2023.08.23.554537 — Posted: 2023-08-24
Unveiling the Robustness of Machine Learning Models in Classifying COVID-19 Spike Sequences
Ali, S., Chen, P.-Y., Patterson, M.
10.1101/2023.08.24.554651 — Posted: 2023-08-24
Prediction of COVID-19 infection risk using personal mobile location data only
Jang, A., Kim, S., Baek, H., Kim, H., Park, H.-L.
10.1101/2023.08.22.23294419 — Posted: 2023-08-24
COVID-19 self-testing: Countries accelerating policies ahead of WHO guidelines during pandemics: A Global Survey.
Sakala, M., Johnson, C., Chirombo, J., Sacks, J. A., Baggaley, R., Divala, T.
10.1101/2023.08.23.23294474 — Posted: 2023-08-24
Risk Factors for Post-Traumatic Stress Disorder (PTSD) in COVID Survivors A Cross-Sectional Study
Dhakal, S., Khatiwada, R. P.
10.1101/2023.08.23.23294470 — Posted: 2023-08-24
Pediatric and Adult Patients with ME/CFS following COVID-19: A Structured Approach to Diagnosis Using the Munich Berlin Symptom Questionnaire (MBSQ)
Peo, L. C., Wiehler, K., Paulick, J., Gerrer, K., Leone, A., Viereck, A., Haegele, M., Stojanov, S., Warlitz, C., Augustin, S., Alberer, M., Hattesohl, D. R. B., Froehlich, L., Scheibenbogen, C., Mihatsch, L. L., Pricoco, R., Behrends, U.
10.1101/2023.08.23.23293081 — Posted: 2023-08-24
Risk of long COVID and associated symptoms after acute SARS-COV-2 infection in ethnic minorities: a Danish nationwide cohort study
Mkoma, G., Agyemang, C., Benfield, T. L., Rostila, M., Cederström, A., Petersen, J. H., Norredam, M.
10.1101/2023.08.22.23294402 — Posted: 2023-08-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).